ArticleBMC endocrine disorders2025
LncRNA MALAT1 knockdown inhibits apoptosis of mouse hippocampus neuron cells with high glucose by Silencing autophagy.
Article in BMC endocrine disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundDiabetes mellitus is a fast-growing metabolic disease worldwide, which is often accompanied by various complications in later stages, such as neuropathy and hippocampal neuron damage. LncRNA plays a acts crucial role in the progressional with occurrence of diabetes mellitus, hippocampal neuron damage, and autophagy. MALAT1, a highly conserved lncRNA, is involved in various disease processes. MALAT1 can regulate the damage and inflammation of hippocampal neuron cells, and is highly expressed in high glucose induced hippocampal neuron cells. However, the role of lncRNA MALAT1 in the apoptosis of mouse hippocampus neuron cells with diabetes mellitus remains unclear.
methodsHere, an 8-week-old C57BL/6J mice diabetes mellitus model was established. MALAT1 expression in mouse hippocampus tissues was analyzed using qRT-PCR with HT22 cells. CCK-8 assays were applied to measure HT22 cell proliferation. HT22 cell apoptosis with autophagy was analyzed using flow cytometry with TUNEL staining, respectively. The BECN1 and ATG7 protein expressions in HT22 cells were analyzed using Western blotting.
resultsBioinformatics analysis in this study found that MALAT1 is highly expressed in the hippocampal tissue of diabetic patients and is associated with the PI3K/AKT signaling pathway. MALAT1 was markedly elevated in mouse hippocampus tissues with diabetes mellitus and high glucose-treated (HGT) HT22 cells. HGT remarkably suppressed HT22 cell proliferation, facilitated apoptosis, and enhanced autophagy biomarkers BECN1 and ATG7 protein; while MALAT1 knockdown remarkably facilitated proliferation, suppressed apoptosis, and reduced BECN1 and ATG7 protein expression in HGT-HT22 cells. Furthermore, activating autophagy could remarkably suppress proliferation, facilitate apoptosis, and enhance BECN1 and ATG7 protein expression in HT22 cells with MALAT1 knockdown.
conclusionsThe present study verified that MALAT1 knockdown inhibits the apoptosis of mouse hippocampus neuron cells with diabetes mellitus by silencing autophagy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.